10.1021/acsabm.9b00036.s001
Parthiban Venkatesan
Parthiban
Venkatesan
Natesan Thirumalaivasan
Natesan
Thirumalaivasan
Hsiu-Ping Yu
Hsiu-Ping
Yu
Ping-Shan Lai
Ping-Shan
Lai
Shu-Pao Wu
Shu-Pao
Wu
Redox Stimuli Delivery Vehicle Based on Transferrin-Capped
MSNPs for Targeted Drug Delivery in Cancer Therapy
American Chemical Society
2019
GSH
Conventional antitumor drugs
TUNEL
FT-IR
side effects
cancer cells
HT
BET
Cancer Therapy Cancer
Targeted Drug Delivery
Redox Stimuli Delivery Vehicle
tumor cells
MCF -7 cells
drug delivery platforms
DOX
PEG
TEM
MSNP
glutathione-triggered intracellular drug release
NMR
BJH
TGA
cancer cells need
2019-03-08 00:00:00
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Redox_Stimuli_Delivery_Vehicle_Based_on_Transferrin-Capped_MSNPs_for_Targeted_Drug_Delivery_in_Cancer_Therapy/7882454
Cancer
has become one of the major diseases of human health around
the world. Conventional antitumor drugs cannot specifically target
cancers and result in serious side effects. To achieve better therapy,
innovative functional drug delivery platforms that will aid specific
targeting for cancer cells need to be developed. In this study, transferrin
(Tf), which can target cancer cells, is covalently anchored onto the
surface of MSNPs via disulfide linkage, which is used for glutathione-triggered
intracellular drug release in tumor cells. The successful functionalization
of redox-responsive MSNPs is confirmed by using BET/BJH, TEM, TGA,
NMR, and FT-IR (BET, Brunauer–Emmett–Teller; BJH, Barrett–Joyner–Halenda).
In addition, polyethylene glycol (PEG) is further grafted onto the
surface of MSNPs to improve the biocompatibility and stability under
physiological conditions for longer blood circulation. Our <i>in vitro</i> studies demonstrate that DOX-loaded MSNP–SS–Tf@PEG
can selectively be internalized into cancer cells via Tf/Tf receptor
interactions, and then, DOX is released in HT-29 and MCF-7 cells triggered
by high GSH concentration in tumor cells. Remarkably, <i>in vivo</i> studies demonstrate that DOX-loaded MSNP–SS–Tf@PEG
can significantly inhibit tumor growth with minimized side effects
through cell apoptosis determined by TUNEL assay, whereas MSNP–SS–Tf@PEG
revealed no significant inhibition. In conclusion, DOX–MSNP–SS–Tf@PEG
with active targeting moieties and a redox-responsive strategy has
been demonstrated as a great effective drug carrier for tumor therapy <i>in vitro</i> and <i>in vivo</i>.